Not really clear why VAF measure is dependent on tumor heterogeneity .. But seems to me this could be side-stepped by single cell sequencing? If so, single cell = less requirement for deep sequencing? And you can deploy NGS capability to broader but shallower coverage (as opposed to smaller target but deeper) .. and change the trade off between VAF sensitivity and breadth ?
Fantastic! Excellent explanations and very accessible. Beautifully done.
I did not get where 80%, 60% is are from 15:56. Why so sure of heterogeneous?
Example to explain
Not really clear why VAF measure is dependent on tumor heterogeneity .. But seems to me this could be side-stepped by single cell sequencing?
If so, single cell = less requirement for deep sequencing? And you can deploy NGS capability to broader but shallower coverage (as opposed to smaller target but deeper)
.. and change the trade off between VAF sensitivity and breadth ?
Because not all tumor cell harbour same variants.
Points briefly explained in video
1) Whole genome/whole Exome/ Targeted sequencing
2) coverage
3) VAF
4) Clinical significance
Superb